Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA. Vilquin P, et al. Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2. Int J Cancer. 2013. PMID: 23553037 Free article.
Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Louveau B, Resche-Rigon M, Lesimple T, Da Meda L, Pracht M, Baroudjian B, Delyon J, Amini-Adle M, Dutriaux C, Reger de Moura C, Sadoux A, Jouenne F, Ghrieb Z, Vilquin P, Bouton D, Tibi A, Huguet S, Rezai K, Battistella M, Mourah S, Lebbe C. Louveau B, et al. Among authors: vilquin p. Clin Cancer Res. 2021 Jul 15;27(14):3876-3883. doi: 10.1158/1078-0432.CCR-20-4050. Epub 2021 May 4. Clin Cancer Res. 2021. PMID: 33947696 Clinical Trial.
Mechanisms of resistance to endocrine therapies for breast cancer.
Heudel P, Vilquin P, Tredan O, Ray-Coquard I, Guastalla JP, Treilleux I, Bachelot T. Heudel P, et al. Among authors: vilquin p. Horm Mol Biol Clin Investig. 2012 Apr;9(2):165-71. doi: 10.1515/hmbci-2011-0001. Horm Mol Biol Clin Investig. 2012. PMID: 25436705
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, Bourgeois H, Petit T, Lortholary A, Plantade A, Briand M, Leconte A, Richard N, Vilquin P, Clarisse B, Blanc-Fournier C, Joly F. Lheureux S, et al. Among authors: vilquin p. Int J Gynecol Cancer. 2012 Nov;22(9):1483-8. doi: 10.1097/IGC.0b013e31826d1438. Int J Gynecol Cancer. 2012. PMID: 23027040 Clinical Trial.
19 results